Page 16 - Morphosys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Today - Breaking & Trending Today

MorphoSys AG: Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023

Conference Call AlertMUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST ....

United States , Thomas Biegi , Eamonn Nolan , Morphosys Agview , Julia Neugebauer , Exchange Commission , Conference Call , Morphosy Annual Report ,

MorphoSys (NASDAQ:MOR) Shares Gap Up to $5.33

MorphoSys AG (NASDAQ:MOR – Get Rating)’s share price gapped up before the market opened on Monday . The stock had previously closed at $5.33, but opened at $5.47. MorphoSys shares last traded at $5.48, with a volume of 18,793 shares. Analyst Upgrades and Downgrades MOR has been the subject of several analyst reports. Morgan Stanley […] ....

Td Asset Management Inc , Jpmorgan Chase Co , Morphosys Company Profile , Morgan Stanley , Opaleye Management Inc , Susquehanna International Group , T Rowe Price Investment Management Inc , Optiver Holding , Get Rating , Price Investment Management , International Group , Management Inc , Morphosys Daily , Nasdaq Mor ,

MorphoSys (NASDAQ:MOR) Shares Gap Down to $5.17

MorphoSys AG (NASDAQ:MOR – Get Rating) gapped down prior to trading on Thursday . The stock had previously closed at $5.17, but opened at $5.00. MorphoSys shares last traded at $5.07, with a volume of 21,356 shares traded. Analyst Upgrades and Downgrades A number of equities research analysts have weighed in on the stock. JPMorgan […] ....

Citadel Advisors , Jpmorgan Chase Co , Susquehanna International Group , Morgan Stanley , Virtu Financial , Optiver Holding , Morphosys Company Profile , Get Rating , International Group , Morphosys Daily , Nasdaq Mor ,

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

EQS-News: MorphoSys AG

/ Key word: Miscellaneous

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL. | April 16, 2023 ....

United States , University Hospital , Steven Stein , Tim Demuth , Johannes Duell , American Association For Cancer Research Annual Meeting , Morphosys Us Inc , Exchange Commission , Xencor Inc , Practice Research Clinical Haematology , American Association For Cancer Research , Drug Administration , Incyte Announce Five Year Results , Showed Prolonged , Durable Responses , American Association , Cancer Research Annual Meeting , Cancer Research , Annual Meeting , Medical Clinic , Chief Research , Development Officer , Chief Medical Officer , Diffuse Largeb Cell Lymphoma , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis ,

Incyte and MorphoSys U.S. Inc.: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary ....

United States , University Hospital , Steven Stein , Johannes Duell , Kaitlyn Nealy , Julia Neugebauer , Christine Chiou , Thomas Biegi , Jenifer Antonacci , Tim Demuth , Public Affairs , Morphosys Us Inc , American Association For Cancer Research , Exchange Commission , American Association For Cancer Research Annual Meeting , Practice Research Clinical Haematology , Xencor Inc , Drug Administration , American Association , Cancer Research Annual Meeting , Cancer Research , Annual Meeting , Medical Clinic , Chief Research , Development Officer , Chief Medical Officer ,